

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. DO: 1450, Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/509,932	09/13/2000	Dagmar Antoni-Zimmermann	788-027	1908	
759	90 07/25/2003				
James V Costigan			EXAMINER		
Hedman Gibson 1185 Avenue of			JAGOE, D	JAGOE, DONNA A	
New York, NY 10036-2601					
,			ART UNIT	PAPER NUMBER	
			1614		
			DATE MAILED: 07/25/2003	19	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Amiliantia				
	Application No.	Applicant(s) ANTONI-ZIMMERMANN ET AL.				
Office Action Summary	09/509,932					
Office Action Summary	Examiner	Art Unit				
THE SAME WAS DATE OF THE SAME	Donna Jagoe	1614				
The MAILING DATE of this communication app Period for Reply	ears on the cover sneet with the (correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be till within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	mely filed ys will be considered timely. In the mailing date of this communication. ED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on <u>04 M</u>	<u> March 2003</u> .					
2a) ☐ This action is FINAL . 2b) ☑ Thi	is action is non-final.					
3) Since this application is in condition for alloward closed in accordance with the practice under a						
Disposition of Claims						
4) Claim(s) 1-9 is/are pending in the application.	un from consideration					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) 1-9 is/are rejected.						
7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	r election requirement					
Application Papers	Globion requirement.					
9) The specification is objected to by the Examiner	r.					
10)☐ The drawing(s) filed on is/are: a)☐ accep	oted or b)⊡ objected to by the Exa	miner.				
Applicant may not request that any objection to the	e drawing(s) be held in abeyance. S	ee 37 CFR 1.85(a).				
11)☐ The proposed drawing correction filed on	is: a)□ approved b)□ disappro	oved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Exa	aminer.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a	a)-(d) or (f).				
a)⊠ All b)□ Some * c)□ None of:						
 Certified copies of the priority documents 	s have been received.					
2. Certified copies of the priority documents	s have been received in Applicat	ion No				
 3. Copies of the certified copies of the prior application from the International But * See the attached detailed Office action for a list of the certified copies of the prior application. 	reau (PCT Rule 17.2(a)).	-				
14) Acknowledgment is made of a claim for domestic						
a) The translation of the foreign language pro	• •					
Attachment(s)	- p	· · · · · · · · · · · · · · · · · · ·				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				

Art Unit: 1614

Claims 1-9 are pending in this application.

In view of the appeal brief filed on 4 March 2003, PROSECUTION IS HEREBY REOPENED. New grounds of rejection are set forth below.

To avoid abandonment of the application, appellant must exercise one of the following two options:

- (1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR 1.113 (if this Office action is final); or,
 - (2) request reinstatement of the appeal.

If reinstatement of the appeal is requested, such request must be accompanied by a supplemental appeal brief, but no new amendments, affidavits (37 CFR 1.130, 1.131 or 1.132) or other evidence are permitted. See 37 CFR 1.193(b)(2).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- 1. Claims 1-9 are rejected under 35 U.S.C. 102(a) as being anticipated by Antoni-Zimmerman et al. WO 99/08530.

The claims are drawn to a composition consisting essentially of 2-methylisothiazolin-3-one (MIT) and 3-iodo-2-propynyl-N-butylcarbamate (IPBC) in a polar or non-polar liquid medium (such as water) and with weight ratios of from 100:1 to

Art Unit: 1614

1:50 to 15:1 to 1:8 and wherein the composition contains MIT and IPBC in a total concentration of from 1 to 20% by weight. Further claims are drawn to methods of combating harmful microorganisms comprising applying an effective amount of the said biocide composition and use as an additive to substances susceptible to infestation by harmful organisms.

Antoni-Zimmerman et al teach a biocide composition for use as an additive in substances which are susceptible to attack by harmful microorganisms comprising a composition of at least 2 active biocide agents of which one is MIT (see abstract). Example 13 on page 34 recites a synergistic composition of MIT and BIT with IPBC. The concentration of the biocides is recited on page 4, lines 1-7. The preferred polar liquid media are water, an aliphatic alcohol having 1-4 carbon atoms a glycol, diethylene glycol, 1,2 propylene glycol dipropylene glycol and tripropyleneglycol (page 4, lines 21-35). Regarding the claim language "consisting essentially of" although the prior art teaches the inclusion of 1,2-benzisothiazolin-3-one (BIT), the transitional phrase "consisting essentially of" limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. In re Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976). Since there is no evidence that the BIT, required by the prior art would materially affect the basic and novel characteristics (there is synergism recited in the combination of example 13 cited above for MIT, BIT combines with IPBC (page 35 lines 23-24). The weight ratios for MIT/BIT appear to be the same as the instantly claimed ratios for MIT/IPBC. The formula can be used as an additive to paints, polymer dispersions,

Art Unit: 1614

plaster systems and cooling lubricants against attack by bacteria, filamentous fungi and yeasts (page 22, lines 1-7).

2. Claims 1-9 are rejected under 35 U.S.C. 102(a) as being anticipated by Theis et al. DE 198 33 894 A1.

The claims are drawn to a composition consisting essentially of 2-methylisothiazolin-3-one (MIT) and 3-iodo-2-propynyl-N-butylcarbamate (IPBC) in a polar or non-polar liquid medium (such as water) and with weight ratios of from 100:1 to 1:50 to 15:1 to 1:8 and wherein the composition contains MIT and IPBC in a total concentration of from 1 to 20% by weight. Further claims are drawn to methods of combating harmful microorganisms comprising applying an effective amount of the said biocide composition and use as an additive to substances susceptible to infestation by harmful organisms.

Thiel et al. teach a composition comprising methylisothiazolinone (MIT) 0.5% and CARBAMAT (3-iodo propynyl butylcarbamate (IPBC)) 0.5% in water (see example 1 on page 3 and see also page 3, lines 2-6) with a pH of from 7 to 7.5 and a concentration of from 2 to 25% after diluting (see abstract). The composition is for use as *inter alia* protection additives and means of preservation and/or corrosion protection additive (page 2, lines 35-38).

Art Unit: 1614

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Valcke et al. U.S. Patent No. 5,714,507 A.

Art Unit: 1614

The claims are drawn to a composition consisting essentially of 2-methylisothiazolin-3-one (MIT) and 3-iodo-2-propynyl-N-butylcarbamate (IPBC) in a polar or non-polar liquid medium (such as water) and with weight ratios of from 100:1 to 1:50 to 15:1 to 1:8 and wherein the composition contains MIT and IPBC in a total concentration of from 1 to 20% by weight. Further claims are drawn to methods of combating harmful microorganisms comprising applying an effective amount of the said biocide composition and use as an additive to substances susceptible to infestation by harmful organisms.

Valcke et al. teach biocide compositions comprising the active ingredients (I) and (II) (column 1, lines 18-27) and further comprising other microbiocides such as IPBC (column 11, line 31) and isothiazolinones such as N-methylisothiazolin-3-one. The weight ratios and pH are not recited. As stated in In re Kerkhoven, 626 F.2d 846, 205 USPQ 1069, at page 1072 (CCPA 1980):

It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition which is to be used for the very same purpose. In re Susi, 58 CCPA 1074, 1079-80, 440 F.2d 442, 445, 169 USPQ 423, 426 (1971); In re Crockett, 47 CCPA 1018, 1020-21, 279 F.2d 274, 276-77, 126 USPQ 186, 188 (CCPA 1960). As this court explained in Crockett, the idea of combining them flows logically from their having been individually taught in the prior art.

Therefore, it would have been prima facie obvious to combine the microbiocidal MIT with the microbiocidal IPBC to form a biocidal composition that is useful as an additive to substances susceptible to infestation by microorganisms. Motivation to combine flows logically from their having been individually taught in the prior art.

Regarding the claim language "consisting essentially of" although the prior art teaches the inclusion of metconazole with a triazole, the transitional phrase "consisting essentially of" limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. In re Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976). Since there is no evidence that the metconazole required by the prior art would materially affect the basic and novel characteristics.

Thus the claims fail to patentably distinguish over the state of the art as represented by the cited references.

No claims are allowed.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna Jagoe whose telephone number is (703) 306-5826. The examiner can normally be reached on Monday through Friday from 8:00 A.M. - 4:30 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3230 for regular communications and (703) 872-9307 for After Final communications.

Art Unit: 1614

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Donna Yagoe Patent Examiner Art Unit 1614

Frederick Krass Primary Examiner Art Unit 1614

dj July 20, 2003